Holen Sie sich die Stockscreener-App
9.09
1.52%
-0.14
Handel nachbörslich:
9.09
Schlusskurs vom Vortag:
$9.23
Offen:
$9.21
24-Stunden-Volumen:
93,744
Relative Volume:
0.73
Marktkapitalisierung:
$336.65M
Einnahmen:
$239.40M
Nettoeinkommen (Verlust:
$104.44M
KGV:
3.0709
EPS:
2.96
Netto-Cashflow:
$-18.50M
1W Leistung:
+2.48%
1M Leistung:
+14.48%
6M Leistung:
-51.18%
1J Leistung:
-30.93%
1-Tages-Spanne:
$8.93
$9.27
1-Wochen-Bereich:
$8.69
$9.46
52-Wochen-Spanne:
$7.10
$21.79
Entrada Therapeutics Inc Stock (TRDA) Company Profile
Firmenname
Entrada Therapeutics Inc
Sektor
Branche
Telefon
857-305-1825
Adresse
ONE DESIGN CENTER PLACE, BOSTON
Vergleichen Sie TRDA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
9.09 | 336.65M | 239.40M | 104.44M | -18.50M | 2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-06 | Eingeleitet | ROTH MKM | Buy |
| 2024-01-05 | Eingeleitet | Oppenheimer | Outperform |
| 2023-04-03 | Eingeleitet | H.C. Wainwright | Buy |
Entrada Therapeutics Inc Aktie (TRDA) Neueste Nachrichten
Layoff Tracker: Pliant Cuts 45% of Staff To Extend Cash Runway - BioSpace
Invesco Ltd. Takes Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Entrada Therapeutics (TRDA) Projected to Post Earnings on Tuesday - Defense World
Analysts Estimate Entrada Therapeutics, Inc. (TRDA) to Report a Decline in Earnings: What to Look Out for - MSN
Arvinas, Entrada cut staff; Merck builds US hub for Keytruda - BioPharma Dive
Legal & General Group Plc Has $344,000 Stock Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Immunic’s stock falls on multiple sclerosis data; Entrada’s layoffs - Endpoints News
JPMorgan Chase & Co. Raises Stock Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Entrada Therapeutics IncApproves Strategic Plan Focusing On DMD ProgramsSEC Filing - marketscreener.com
Russell Investments Group Ltd. Raises Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Geode Capital Management LLC Decreases Stock Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
LPL Financial LLC Raises Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Trend Tracker for (TRDA) - news.stocktradersdaily.com
Vanguard Group Inc. Has $25.32 Million Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
CandE Benchmark Research Case Study – Entrada Therapeutics - ere.net
KLP Kapitalforvaltning AS Invests $36,000 in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
American Century Companies Inc. Purchases 8,985 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Ultragenyx (RARE) Soars 9.2%: Is Further Upside Left in the Stock? - Yahoo Finance
HC Wainwright Issues Negative Forecast for TRDA Earnings - MarketBeat
Lacklustre Performance Is Driving Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) 27% Price Drop - simplywall.st
HC Wainwright Issues Pessimistic Forecast for TRDA Earnings - Defense World
(TRDA) On The My Stocks Page - news.stocktradersdaily.com
Entrada Therapeutics (NASDAQ:TRDA) Receives Buy Rating from HC Wainwright - Defense World
Entrada Therapeutics Gains Momentum Amid Exon-Skipping Advances and Regulatory Approvals - TipRanks
Entrada Therapeutics stock rating holds with $20 target By Investing.com - Investing.com UK
Entrada Therapeutics stock hits 52-week low at $9.74 By Investing.com - Investing.com UK
Charles Schwab Investment Management Inc. Boosts Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Roth/MKM maintains Buy on Entrada stock, $23 target By Investing.com - Investing.com Canada
Positive Outlook on Entrada Therapeutics Inc Due to Promising Developments in Duchenne Muscular Dystrophy Treatment - TipRanks
Entrada Therapeutics gets approval to start trial of its DMD treatment in the UK (TRDA:NASDAQ) - Seeking Alpha
Entrada Therapeutics rises on UK approval for muscle-wasting drug study - TradingView
Entrada’s ENTR-601-45 gains clearance in UK to enter clinic for Duchenne muscular dystrophy - BioWorld MedTech
Entrada Therapeutics begins Duchenne study in UK By Investing.com - Investing.com Australia
Entrada Therapeutics begins Duchenne study in UK - Investing.com India
Entrada Therapeutics Gains UK Approval for DMD Study - TipRanks
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping - The Manila Times
Major Breakthrough: Entrada's DMD Drug Gets Green Light for UK Clinical Trials - Stock Titan
Bank of New York Mellon Corp Lowers Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Entrada Therapeutics stock hits 52-week low at $10.21 - Investing.com
Entrada Therapeutics stock hits 52-week low at $10.21 By Investing.com - Investing.com UK
Entrada Therapeutics CFO sells $19,035 in stock By Investing.com - Investing.com South Africa
Entrada Therapeutics CFO sells $19,035 in stock - Investing.com India
Long Term Trading Analysis for (TRDA) - news.stocktradersdaily.com
Entrada Therapeutics stock hits 52-week low at $10.25 By Investing.com - Investing.com Australia
Entrada Therapeutics stock hits 52-week low at $10.25 - Investing.com
Entrada Therapeutics (TRDA) Expected to Announce Earnings on Wednesday - Defense World
Entrada Therapeutics stock hits 52-week low at $11.3 amid market shifts - Investing.com Canada
Brokers Offer Predictions for TRDA Q4 Earnings - Defense World
What is William Blair’s Estimate for TRDA Q1 Earnings? - Defense World
Results: Entrada Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - simplywall.st
Finanzdaten der Entrada Therapeutics Inc-Aktie (TRDA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.39%
3.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):